<SEC-DOCUMENT>0001437749-25-006832.txt : 20250310
<SEC-HEADER>0001437749-25-006832.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310161302
ACCESSION NUMBER:		0001437749-25-006832
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250310
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		25723831

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crvo20250310_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:crvo="http://www.crvo.com/20250310"><head>
	<title>crvo20250310_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 3/10/2025 2:10:07 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20258K" name="dei:AmendmentFlag" id="ixv-300">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20258K" name="dei:EntityCentralIndexKey" id="ixv-301">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="crvo-20250310.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20258K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-03-10</xbrli:startDate>
<xbrli:endDate>2025-03-10</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 1pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20258K" name="dei:DocumentType" id="ixv-22"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-35"><b>March 10, 2025</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityRegistrantName" id="ixv-43"><b>CervoMed Inc.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-55"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityFileNumber" id="ixv-59"><b>001-37942</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityTaxIdentificationNumber" id="ixv-63"><b>30-0645032</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></div>
			</td>
			<td style="vertical-align:top;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:15.3%;">&#160;</td>
			<td style="vertical-align:middle;width:15.3%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine1" id="ixv-87"><b>20 Park Plaza, Suite 424</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressCityOrTown" id="ixv-91"><b>Boston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-93"><b>Massachusetts</b></ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressPostalZipCode" id="ixv-97"><b>02116</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20258K" name="dei:CityAreaCode" id="ixv-110"><b>617</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20258K" name="dei:LocalPhoneNumber" id="ixv-112"><b>744-4400</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 1pt auto"/>
<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-311">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-312">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-313">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-314">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:Security12bTitle" id="ixv-315">Common Stock, $0.001 par value</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:TradingSymbol" id="ixv-316">CRVO</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-317">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-318">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Regulation FD Disclosure</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Press Release</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 10, 2025, CervoMed Inc. (the &#8220;Company&#8221;) issued a press release announcing positive results from the first sixteen weeks of the open-label extension phase of the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information in this Item 7.01 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 8.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Other Events </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information set forth in the first paragraph and the information under the heading &#8220;16-Week Results from the Extension Phase of the Phase 2b RewinD-LB Study&#8221; of Company&#8217;s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current&#160;Report&#160;on&#160;Form&#160;8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 9.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Financial Statements and Exhibits</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><i>Exhibits</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following exhibit relating to Item 7.01 is furnished and not filed:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:41.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:4.6%;">&#160;</td>
			<td style="vertical-align:middle;width:41.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align:top;width:41.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_787624.htm" style="-sec-extract:exhibit;">Press Release, issued March 10, 2025.</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:41.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:23.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 10, 2025</div>
			</td>
			<td colspan="2" style="vertical-align:middle;width:1.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CervoMed Inc.</b></div>
			</td>
			<td style="vertical-align:middle;width:5.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&#160;</td>
			<td style="vertical-align:middle;width:1.9%;">&#160;</td>
			<td style="vertical-align:middle;width:16.2%;">&#160;</td>
			<td style="vertical-align:middle;width:5.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&#160;</td>
			<td style="vertical-align:middle;width:1.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:16.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ William Elder</div>
			</td>
			<td style="vertical-align:middle;width:5.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&#160;</td>
			<td style="vertical-align:middle;width:1.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:</div>
			</td>
			<td style="vertical-align:middle;width:16.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William Elder</div>
			</td>
			<td style="vertical-align:middle;width:5.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&#160;</td>
			<td style="vertical-align:middle;width:1.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</div>
			</td>
			<td style="vertical-align:middle;width:16.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer &amp; General Counsel</div>
			</td>
			<td style="vertical-align:middle;width:5.1%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_787624.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_787624.htm</title>

	<!-- Generated by ThunderDome Portal - 3/10/2025 7:08:11 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><img alt="cm01.jpg" src="cm01.jpg"></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p&lt;0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Improvement (p=0.035 against either old capsules or placebo) also demonstrated on</i> the <i>Alzheimer's Disease Cooperative Study</i><i> -</i><i> Clinical Global Impression of Change (CGIC)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Company to host investor webcast at 5:00 PM ET today to discuss results</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston, March 10, 2025 </b>&#8211;<b> </b>CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced positive results from the first 16 weeks of the extension phase of the Phase 2b RewinD-LB study of neflamapimod in the treatment of dementia with Lewy bodies (DLB).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;This is a great day for patients and families impacted by DLB, as well as the DLB clinical community. The magnitude of the effect demonstrated on the CDR-SB and the CGIC, both clinically meaningful endpoints, as well the apparent beneficial effect on the incidence of participant falls, suggests that neflamapimod has the potential to fundamentally change the disease course of DLB and our approach to treating the disease,&#8221; said James E. Galvin, MD, MPH, Professor of Neurology at the Miller School of Medicine in Miami, Co-Principal Investigator of the RewinD-LB study and member of the Board at the Lewy Body Dementia Association (LBDA). Continued Dr. Galvin, &#8220;To date, there is not a single drug approved in the U.S. for the management of DLB. My colleagues in the DLB clinical community and I look forward to working with CervoMed and regulatory authorities to advance neflamapimod through phase 3 and the regulatory approval process.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;As presented at the recent International Lewy Body Dementia Conference, our working hypothesis for the failure of neflamapimod during the initial 16 weeks of the study is that the investigational drug capsules utilized in that phase of the trial delivered lower than expected plasma drug concentrations and effectively underdosed participants. Consistent with this hypothesis, the results announced today demonstrate the new batch of capsules led to both higher plasma drug concentration levels and improvements on the metrics used as the primary endpoint and a key secondary endpoint in the initial phase of the study. Further, the consistency and magnitude of the clinical effect of neflamapimod on the CDR-SB are similar to our Phase 2a study results and we believe demonstrate proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies&#8221;, said John Alam, MD, Co-Principal Investigator of the RewinD-LB study and CEO of CervoMed. &#8220;We are excited to complete the full 32-weeks of the extension phase of the study and look forward to engaging with regulatory authorities to discuss finalizing our Phase 3 plans after these additional data are available later this year.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="cm01.jpg" src="cm01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;The results from the extension phase of the RewinD-LB study are highly persuasive. It is rare in dementia clinical research to see results with the magnitude of effect and statistical strength as was seen on the CDR-SB. At the same time, the findings are similar to what was seen in the Phase 2a clinical study and I believe are the result of having utilized a targeted therapy such as neflamapimod as well as aligning the therapy with a DLB patient population that is well suited to respond to its mechanism of action&#8221;, said John-Paul Taylor, MBBS(hons) MRCPsych PhD, Professor of Translational Dementia Research at Newcastle University, United Kingdom (UK) and the principal investigator for the UK.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>16-Week Results from the Extension Phase of the Phase 2b RewinD-LB Study<sup style="vertical-align:top;line-height:120%;">1</sup></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><u>Overview</u></i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Of the 159 participants randomized in the initial 16-week double-blind, placebo-controlled (&#8220;Initial&#8221;) phase of the study, 152 completed the Initial phase and 149 entered the extension phase (&#8220;Extension&#8221;), during which all participants received neflamapimod. Though study participants and site personnel were aware that the treatment for all participants during the Extension phase was neflamapimod (i.e., treatment was &#8220;open label&#8221; neflamapimod), they were not aware of which batch of capsules was administered to any given participant during the first 16 weeks of the Extension. Of the 149 participants who entered the Extension, 55 received the same batch of capsules (&#8220;Old Capsules&#8221;) utilized in the Initial phase throughout the first 16 weeks of the Extension and 94 received a new batch of capsules (&#8220;New Capsules&#8221;) for all or a portion of those 16 weeks; 46 starting at day 1 of the Extension, 22 starting at week 4 of the Extension, and 26 starting at week 8 of the Extension).<sup style="vertical-align:top;line-height:120%;">2</sup></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">87.3% of Old Capsule recipients and 91.5% of New Capsule recipients who entered the Extension completed the first 16 weeks of treatment in this phase.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 1pt auto 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">1</sup>Though all analyses reported are exploratory in nature, along with 95% confidence intervals, p-values are reported to provide a measure of the probability that any differences identified between the samples are due to chance.<br>
<sup style="vertical-align:top;line-height:120%;">2</sup>Except as otherwise indicated, references to &#8220;New Capsule&#8221; data in this press release include these 94 participants as a single cohort.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div><img alt="cm01.jpg" src="cm01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><u>CDR-SB Results</u></i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As specified by the protocol and statistical analysis plan, linear Mixed-effects Model for Repeated Measures was utilized to analyze the change from baseline in CDR-SB, the metric used as the primary endpoint for the Initial phase of the study.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From the end of the Initial phase of the study (i.e. Day 1 of the Extension) through to Week 16 of the Extension, the change in CDR-SB was lower in the New Capsule group compared to the Old Capsule group (difference=-0.73, 95% CI: -1.14, -0.32; p&lt;0.001).</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When analyzed from baseline of the study overall through to Week 16 of the Extension, (i.e., including all data from the first 32 weeks of the study, from Day 1 of the Initial phase through to Week 16 of the Extension), the New Capsules demonstrated a positive benefit compared to placebo (difference= -0.45, 95% CI: -0.78, -0.15; p=0.003).</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The difference for both comparisons in the participants whose screening plasma ptau181 was &lt; 2.2 pg/mL, the cut-off in the Phase 2a study for evidence of Alzheimer&#8217;s disease related co-pathology, were more pronounced.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><u>CGIC Results</u></i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On CGIC, which was administered at Week 8 of the Extension, administration of the New Capsules led to an improved score (4.02 vs. 4.46 with Old Capsules, p=0.035), indicating less worsening with New Capsule administration. A greater magnitude difference was also observed in participants with screening plasma ptau181 &lt; 2.2 pg/mL (3.90 with New Capsules vs. 4.45 with Old Capsules, p=0.011).</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, in a within-subject analysis (i.e., comparing results in participants who received placebo in the Initial phase and New Capsules in the Extension), the CGIC score was reduced in participants administered the New Capsule compared to placebo (3.94 vs. 4.46, p=0.035).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><u>Safety</u></i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Both Old and New Capsules demonstrated comparable tolerability profiles and no new safety signals were identified during the Extension.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The incidence of falls was lower in participants who received New Capsules compared to those who received Old Capsules during the Extension (7.4% vs. 14.5% for all participants; 4.0% vs. 15.4%, p=0.025, for participants with screening plasma ptau181 &lt; 2.2 pg/mL).</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The incidence of falls measured during the Extension were also lower in participants who received New Capsules compared to those who received placebo during the Initial phase of the study (7.4% vs. 18.8% for all participants, p=0.04; 4.0% vs. 19.7%, p=0.007, for participants with screening plasma ptau181 &lt; 2.2 pg/mL).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="cm01.jpg" src="cm01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><u>Pharmacokinetics</u></i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As reported previously, in a within-subject comparison (N=13), the mean plasma drug trough concentration was significantly higher (5.1 vs. 4.0 ng/mL, p=0.03) with the New Capsules than in the Old Capsules. Analyses conducted to date suggest the lower&#8211;than-expected bioavailability with the Old Capsules is related to the to the age of the capsules and the development of inferior dissolution kinetics with extended aging, rather than chemical degradation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Conference Call / Webcast Details</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed will host a conference call and webcast to review and discuss the 16-week results from the Extension phase of the Phase 2b RewinD-LB study today, Monday, March 10, 2025, at 5:00 PM ET. Participants should dial 1-877-425-9470 (domestic) or 1-201-389-0878&nbsp;(international) with the code 13752218.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To access the Call me&#8482; feature, which avoids having to wait for an operator, click&nbsp;<u>here</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The live webcast and replay will be available&nbsp;under &#8220;Events &amp; Presentations&#8221; in the Investor Relations section of the Company&#8217;s website,&nbsp;<u>https://www.cervomed.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The results from the extension phase of the RewinD-LB study have been accepted as an oral presentation at the International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurologic Disorders in Vienna, April 1-5, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Dementia with Lewy Bodies (DLB)</b><br>
DLB is the third most common degenerative disease of the brain (after Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease). Patients with this disease accumulate protein deposits, called Lewy bodies, in the brain&#8217;s nerve cells. This negatively affects cognitive ability, including attention, judgement, and reasoning, along with motor function. Patients with DLB incur higher healthcare costs, have longer hospitalizations, report lower quality of life, and have caregivers with higher levels of distress when compared to patients with Alzheimer&#8217;s disease. No treatments for DLB have been approved by the&nbsp;U.S.&nbsp;Food and Drug Administration (FDA) or&nbsp;European Medicines Agency, and there are few drugs in development. The current standard of care is cholinesterase inhibitor therapy, which is approved for use in AD, but in DLB patients typically improves cognition transiently, and does not impact the motor component of the disease.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Neflamapimod</b><br>
Neflamapimod is an investigational, orally administered small molecule brain penetrant drug that inhibits alpha isoform of the p38MAP kinase. In preclinical studies, neflamapimod reversed synaptic dysfunction, including and particularly within the part of the brain most impacted in DLB &#8211; the basal forebrain cholinergic system. In Phase 1 and Phase 2 clinical studies involving more than 400 participants, neflamapimod has been shown to be generally well tolerated. Results from the AscenD-LB Phase 2a clinical study demonstrated that neflamapimod improved dementia severity (assessed by CDR-SB) compared to placebo and improved functional mobility (assessed by TUG test) compared to placebo. At the highest dose evaluated, neflamapimod also improved results on a cognitive test battery. The treatment response in AscenD-LB in the participants who did not have AD co-pathology (as assessed by a blood biomarker, plasma ptau181) was substantial (effect size &gt; 0.7) and greater than the overall study population.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="cm01.jpg" src="cm01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Study in Dementia with Lewy Bodies</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Initial phase of RewinD-LB is a randomized, 16-week, double-blind, placebo-controlled clinical study evaluating oral neflamapimod (40mg TID) in 159 patients with DLB. Patients with AD co-pathology, as assessed by plasma ptau181 levels, were excluded from the study. Compared to patients with &#8220;pure&#8221; DLB &#8211; who may comprise up to 50% of the total diagnosed DLB patient population at any given time &#8211; DLB patients with AD co-pathology have significant, irreversible neuronal loss in the hippocampus. The primary endpoint in the study is change in the CDR-SB, and secondary endpoints include CGIC, the TUG test, and a cognitive test battery (NTB). The RewinD-LB study is funded by a&nbsp;$21.3 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, which is expected to be disbursed over the course of the study as costs are incurred. The study includes 43 sites across in&nbsp;the United States, the&nbsp;United Kingdom, and&nbsp;the Netherlands). Participants completing the 16-week Initial phase of the study were able to continue in the study while receiving neflamapimod treatment for an additional 32-week Extension phase, which includes a pre-specified data readout after the first 16 weeks.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>National Institute on Aging Grant</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research reported in this press release was supported by the National Institute On Aging of the National Institutes of Health under Award Number R01AG080536. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div><img alt="cm01.jpg" src="cm01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the therapeutic potential of neflamapimod; the anticipated timing and achievement of clinical and development milestones, potential discussions with regulatory authorities related to the Initial and Extension phases and clinical development of and approval process for neflamapimod; any other expected or implied benefits or results, including that any future clinical results observed with respect to neflamapimod in the Initial and Extension phases will be replicated in later studies; the timing of the initiation of any phase 3 study or other additional clinical trials evaluating neflamapimod in DLB, including as a result of the Company&#8217;s need to acquire sufficient funding therefor. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Investors@cervomed.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Argot Partners</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>cervomed@argotpartners.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">212-600-1902</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crvo-20250310.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/10/2025 2:10:29 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:crvo="http://www.crvo.com/20250310" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crvo.com/20250310">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20250310_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20250310_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20250310_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.crvo.com/20250310/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="crvo_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>crvo-20250310_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/10/2025 2:10:29 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.crvo.com/20250310/role/statement-document-and-entity-information" xlink:href="crvo-20250310.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.crvo.com/20250310/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>crvo-20250310_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/10/2025 2:10:29 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>crvo-20250310_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/10/2025 2:10:29 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.crvo.com/20250310/role/statement-document-and-entity-information" xlink:href="crvo-20250310.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.crvo.com/20250310/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cm01.jpg
<TEXT>
begin 644 cm01.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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ML!\@7W4<8],'UKWJOFLKS2AC\/'$T'H^G5/JGYH^IPN(C7I1JQZH****](Z
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M\5(_C7X__9H\;>1Y$/BSX:IK+0C/[M;B:*4H/IOQ^%>V_P#! +XCQ?\ !/\
M_;Q_:0^ /B>]-IHME9'Q38RSG&8[.-9&D'^_97$+GU\D^E>G/*Z?U%5HWY]W
M\G9G%'&3^LN#^'_@7/K7]M[_ (.+?@]^PO\ M+Z_\+M=\,^.O$.M>&X[<WUU
MH\%L]JDDT2RB+,DRMN577/'!.*ZS]H/_ (+D_#;]G/\ 8P^%'QOU?PMXUO/#
M?Q=*KI=E:0VYO;3,+R_O@TH0<(1\K-R17\]?[1D6I_M(^!OB#^TEK'G!_'OQ
M0FTNRW'"E7M9KR0#U\N,VJ#TK[1_X*D\_P#!OO\ L2?[\?\ Z03UV2R?#Q=&
M+O=NTM?*[,%CZKYWT2NOO/KY_P#@[D^!48S_ ,*\^*^/^O6RX_\ )BO?_P#@
MH/\ \%U_AK_P3C^(/A3PYXM\*^-]9N_%^@)XAM9-)AMWCA@>1HPC^9*AWY4]
M 1C'-?CW^Q[^W7^Q7\,/V=O!WA?XF_LMW/CSQ[80BVUCQ J6Q74IFF8K)\TR
MMPK(.0/NUZ'_ ,';/DVG[8/PN^QQ_9H(OAN/(C7CRE%[/M'X#'Y5/]E8=XJ-
M%TY17O;O>W8?UVI[%U%)-Z;+8^W/!7_!V1^SIXAUB.VU?PY\4O#MO(P4W<VD
MP7,47NPAF9\?12?:OT3^!7Q[\'?M,?"_2_&?@/Q%IGBCPQK2&2SO[&7?')@X
M92#AD=3PR, RD8(!KX%^(G_!!#]G;X^_L":=/H7P_P!)\&>.[SPA;ZG8Z_I+
M203I??8UD#2KNV2QO)]]6!R"<$'!KXN_X-)/VC=;\-_M.^/OA1/<32>'O$NA
M'Q#':;BT=I?VLL44DB ]/,CE ;'7RDSTKAJX3#5:$ZV%NG#=/L=$*]:%2,*U
MGS;6/W[HI$^Z**\8](4]*^-?C/\ MP/\5?&?C#PKX1G\C0O".I-H6HZE&^'O
M[Z-5:XBC(^['$65"1RSAQT7G[*/2ORL_X)+-X9^ GQX^(_PL^*TMNOC"3Q9?
M:EI<NH/MM99I927B^;@R, DBEN&#G'(&?/SK)<;F>65J. ERSTN]=(W]YJVO
ME\SYGB#-X82MA\-4FH*M)QN]KI72OTOT[['2?LP_\$S[SXG_ +7<WQ UVP.G
M> =+NX=5M()%VOK-X%5\*O:%9!N9C]X_*.,D?I:14321VEN6+)%%&N=Q("JH
M]^@%<]\-?BKH_P 7--O+_0+H:AI=I>26*7T7-O=R1\2&)NCHK93<."RL 3BO
M2IU,3+"T:->3E[*,87?DK7]7U'P_P]EV2J=+"*TJLG.7=O\ R5[);+YGP7^T
M9XQO?^"2W_!2_P 0_'36M/U"Y_9^^/=A8:;XTU.RMWG/@O6K-3%;7UPB M]F
MEB.UG ^5LGLH;[B\+?M,_#KQMX C\5:3X\\&ZCX:FA%PFJ0:Q;O:;",[C)OV
MC@\Y/'>NOU?1+3Q#IMQ97]K;WME=QM#/;W$2RQ3HPPR,K9#*1U!&#7R]KO\
MP0\_9*\2>*Y=:NO@+X!-[-+Y\BQ6KPVTCYSDVZ,(3SVV8K?VM.HE[6Z:TNM;
MVV/>4)1TA:P_]GC_ (*<Z?\ MC_M9:EX+^$7AF7QG\-/"=LX\2?$E;LPZ/%?
M_P %A8C8?MLG=W1@B#/+<9\3_P""7/Q#\(>"?VNOVVXO$NO>&M(FG^+\KPIJ
M=[!;O(HLH02HD()&>,CC.:^^_ ?P]T+X7^%;/0O#>C:7X?T33D\NTT_3K5+6
MVMU]$C0!5_ 5XC\2_P#@DS^S7\8O'VK>*/%/P3^'VO\ B'7KEKS4-0O=+26>
M\F;[SNQZDXJJ=:BN:-FDTO-Z.^H2A-V>[1Z_X&^)/@SQIJ4UMX:U_P +ZM=0
MQ^9+%IE]!/(B9QN98V)"Y.,GC-?F/_P3D_8>\-_\%"/^".WQ%^'7B&>YTV:\
M^)GBJXTC5[5REQHU\FH2^3<(01D DADZ.C,IZY'W]^SI_P $^_@I^R-XJOM;
M^&/PQ\(>!M7U.U^PW=WI%BMO+<0;P_EL1U7<H./4"NV^#_P,\(?L_>%9]$\%
M>'=,\,Z1<WT^I2VEA"(HI+F=]\TI _B=B23W-1&NJ::IWW33]!NFY6YO,^(/
M^"$>M^#?A/X<\9? S4OASX4^%WQ\^&,R6_C*VTRU$1\66_ M]:BD;,DT,RE2
M<L0CN<!0P%=C_P %P_A/K,7[/7ACXY^#;5KGQ[^S;K\/C>P2,'?>Z>F$U*TX
MZK);%F(_Z9"OJ+6?V;? GB'XWZ3\2KSPKHTWC[0[)]-L=?, 6_M[9\[H!(,$
MQG<3M.1DUUVM:+:^(-(NM/OK>&\L;Z%[>XMYE#QSQNI5T8'@J02"#U!IO$KV
MWMDO5?G\A*E^[Y/Z\C\__P#@GEXNL?\ @I)_P45^(W[3UDSWOP\\"Z5!\._A
MS+(A"RLZ)=:K>(#T8R2)#GT5AVK7_P""F'A/Q5^R9^U]\.OVN?"7A[4_%NA^
M$]'N/!_Q(T72X3-?OH,T@F2_@C',K6TV79!R5]@2/L;X(? ?P=^S9\.K/PCX
M"\-:1X2\,:<SM;:;IEN(+>%G<NY"CN6))/O76NF['M3EB5[7FBO=M:WE_7XA
M&E[EI;[W\SS#X!_MG?"K]IWX=VOBKP)\0/"OB/0[J(2B:VU&/? .ZRQDAXG'
M.5< C'(KXW_X*:_M:6G[?=G>_LC_  !U.S\9^+_'QCLO&_B#2Y!=:3X#T,R*
M;J6YN$S']HD0&-(02Q+G(!QGW_XN?\$;_P!E[XY^,Y_$/B;X(^!KS6;QM]S=
M6]HUDUTW=I1 R"0GN6!S7L7P,_9Q\!_LS>"T\.?#SP=X<\%Z&AW?8]'L([2.
M1O[S[ "[?[3$GWHA4HTY*I3NVMKVT_S_  "4:DERRM8_!_\ X.O? ^G_  M^
M,WP&\-:2K1:7X<^'TFFV:$\K#!<)'&#]%451_P"#BWX=:S^S=^U'\-OBYX:N
M[K25^*GPY&CZA>0\>9)%:"UN8B?^FEG/$I]E]J_<C]HG]@OX-_M<:[I^I_$W
MX;^%/&^H:3;-9VEQJUF)Y+>%FW-&I/12W./6KOQX_8O^%7[4/A/1="^(G@'P
MSXQT?PZV_3+35+-9X[$^7Y9\L'[OR87Z 5Z.'SB--4E*+?+>_G<Y*N!<G-I[
MVM\C\#/^"BG[.)_9>_X(._LF:1<VQM=6\4>(;SQ5J*$8/G7EF\J CU6%H5_X
M#74?\%2./^#??]B3/'[R/_TAGK]S/CI^QC\*OVF_"6AZ#X_\ ^&?%NC>&GWZ
M59:C9K+#IY\OR\QKT7Y/E^E9?CO_ ()_?!;XF_"/PQX!\0?#/PEK'@OP80="
MT:ZLE>TTK"%/W2?P_*Q'T-53SB*<'.+;C)R?S%+ /WDGHTE]Q^#7[%W_  4?
M_8M^"/[+W@OPW\3/V9)/''C[1+4QZOKRZ1I\W]H3><[K)ODE5SA2@RP!^6NH
M_P"#LN]B\1?M>_"BXMD,$-_\-UDB1NL:O>SE0<>@(K]@C_P1?_94QS\ _AK^
M.E)7<_';_@GM\$OVGM=TS4_B%\,?"/B_4-&L5TVQN-3L5F>UM@Q80H3T0,2<
M>]5'-:$,3&O",NM[N^_83P55T73;73IV/R0^+O\ P=->'M*_8OA\!?#KP!XD
MM/&">&8M 76=;N+>*RT]A;+ ]PB1NSR,,$HIVC.TGC(._P#\&H/[ OB?PEKG
MBKX]^)=*O-*T75M)'A[PM]LC:.74T:59;F\53@^5F.-%?&'.\C@9/Z8>!_\
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MW;RV"BBBN,]X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45745325145024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">CervoMed Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Mar. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">20 Park Plaza, Suite 424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD9N!XSN'&R]\M3;VACOL9W3%9LS\F4T57+FE2LQ3)C27@BBV'#@C_^8V"&U
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M4=@&\'PII3E<V*UM^<_$\#]02P,$%     @ H(%J6I^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MH(%J6B]<[CON    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ H(%J6IE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "@@6I:U/DB
M)DD$  "E$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ H(%J6I^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crvo20250310_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crvo.com/20250310/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvo-20250310.xsd</File>
    <File>crvo-20250310_def.xml</File>
    <File>crvo-20250310_lab.xml</File>
    <File>crvo-20250310_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="crvo20250310_8k.htm">crvo20250310_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvo20250310_8k.htm": {
   "nsprefix": "crvo",
   "nsuri": "http://www.crvo.com/20250310",
   "dts": {
    "schema": {
     "local": [
      "crvo-20250310.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "crvo-20250310_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvo-20250310_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvo-20250310_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvo20250310_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.crvo.com/20250310/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20250310_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20250310_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.crvo.com/20250310/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-25-006832-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-006832-xbrl.zip
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M,ME=P&65K<V(+LBZ_^+G3U!+ P04    " "@@6I:\@FXJM<$  #E+   %0
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M+S78=;K8<0BO),&&OW\\EZ@?]<]>O/,O4$L#!!0    ( *"!:EH1;!GU=A
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M%6D$HL)\YN*E#$&H [Y8,MT+J)34JO#:&*[+4.9\.=)+S^7/</()AZF1U &
M RV"77$)XT  :>!BUI*Z^OH,[(P7>7A4>-)4J?#[T=(S:1OT0RID><DJDXRR
M:Z"D#FT.2Q>?/GY>GE')!WSZC PI1'SXJM1<^-;9KZ?9QY85:7,3W%#>O3CZ
MU+8^=MM'GZVCD\MVMT&H/Z$SN5B@+2PWK?]6[U7_S6JZ&0C_.NXN!0'Q<!,
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MU1S^+)BAZWF6FQL"K-C(?DR*PWZOWQ^(&]L3)JEF 7;Y''_9HE]@ADB-S::
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M@^0[S4U?0:AT /QP$/[IR0*5B100<5(F0J5Q9C0LMUH1WB<SY-9PGF,P5"?
M96%5;E8W48,YUU@Q,VHP.LKI%%@+[@Z TT":F=MS9@I"E 0YS 1L8(F(0RMT
M6@Z.BIV<C0Q8DC0;P@HW"!=PH;F10+WP",)"S]'=;1TZK<&AL%+'XI\2C_Y%
M3[R2"0@+H/PS^/_B'QUQD9L)R&0X/U*:F0H7R [Q86]UDH! ^A#-C$EP!! C
M[)<UK[<:#KD#1-F]R!$J&8IXXJMZ*@M^(CZD34NXA;F:CU48<6)D'OLYO3:^
MJ#2Z$2P0C@(53['QYN1LM-F#:>&GM 0,.,NK?7D<!<X-V-'!!^8*L34UP..%
M!2@EBH4D0?!&!5K^J?>A1XA<$.JEP)X\90/@>^(MG(X!<,AIB7B=WH&^M,5S
MD.;F&I]XB[N#<[HU^34>$_&'P-MP;*ZF98(P6Z"_8&9R8&8P"=PCXQN)R-9
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MH$'#T^/&CSIMG&(#Z'2$/?&RS)&-\-XC#Z#(,;*VC K<P(N-%NJTY!4@E]5
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M8QWXDU75]$Y(MVPE)WJ0"8)=7H"\HH> N  >"#?(FD.I(8]Z8L2ZB@6#010
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M[(F1S\/#$MPR<BES6*7O6R;0322P71,2?%@WE#>/M7%%E6PKA04T5%1M0SC
MQ8O=![8G\26Z?K"OEW$]2GRYO\;Z<(V5L=I:DY0$)$]E/"_EY\?H"\6*THX
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M0^I/F5<Y >1&Z]6I,2IV]C%%"92DLW'\ZQ)04KSD\:ULTO9!C](4*>:2T[0
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M2P$"% ,4    " "@@6I:<5WG^&4#  !N#0  $0              @ $
M8W)V;RTR,#(U,#,Q,"YX<V102P$"% ,4    " "@@6I:\@FXJM<$  #E+
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M,C4P,S$P7SAK+FAT;5!+ 0(4 Q0    ( *"!:EIQD$T<?1T  &2)   -
M          "  14D  !E>%\W.#<V,C0N:'1M4$L%!@     &  8 A $  +U!
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>crvo20250310_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvo-20250310.xsd" xlink:type="simple"/>
    <context id="d20258K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2025-03-10</startDate>
            <endDate>2025-03-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20258K" id="ixv-300">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20258K" id="ixv-301">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20258K" id="ixv-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20258K" id="ixv-35">2025-03-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20258K" id="ixv-43">CervoMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20258K" id="ixv-55">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20258K" id="ixv-59">001-37942</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20258K" id="ixv-63">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20258K" id="ixv-87">20 Park Plaza, Suite 424</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20258K" id="ixv-91">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20258K" id="ixv-93">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20258K" id="ixv-97">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20258K" id="ixv-110">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20258K" id="ixv-112">744-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20258K" id="ixv-311">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20258K" id="ixv-312">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20258K" id="ixv-313">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20258K" id="ixv-314">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20258K" id="ixv-315">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20258K" id="ixv-316">CRVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20258K" id="ixv-317">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20258K" id="ixv-318">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
